Medicare Advantage insurers no longer have to show that their annual quality improvement work does anything to close health gaps between enrollees of different races, incomes or backgrounds. Under a Centers for Medicare & Medicaid Services final rule published April 6, 2026, that requirement disappears from the regulations governing MA quality improvement programs starting with contract year 2027. The change sits inside a wider rollback of built-in health-equity mandates for the private plans that already cover a majority of Medicare beneficiaries, and it raises a real question about where the billions of dollars tied to plan quality scores get spent next.
CMS’s CY2027 Rule Strips the Health-Disparities Mandate From MA Quality Programs
The provision sits inside the “Reducing Regulatory Burden and Costs” section of the CY2027 Medicare Advantage and Part D final rule, which CMS built around Executive Order 14192, the White House’s deregulation directive. Before this rule, an MA plan’s quality improvement program — the standing internal structure every plan must run to identify and fix gaps in care — had to specifically account for disparities tied to race, ethnicity, sex or other demographic factors. That structural requirement is now optional, not mandatory, for the quality improvement programs plans build for contract year 2027.
CMS states the change plainly: the agency is eliminating the requirement for MA quality improvement programs to include activities that reduce health disparities. The fact sheet frames the move as burden reduction, not a verdict on the underlying goal, grouping it with other CY2027 provisions marketed as easing paperwork — among them a waived call-center staffing requirement for a low-income drug program and loosened rules on when agents and brokers may contact beneficiaries. Nothing in the final rule stops a plan from continuing disparities-focused quality work voluntarily; it only removes the mandate that had forced every MA plan to include it.
The change is not a proposal still working through comment periods — it is part of a rule CMS finalized and published in the Federal Register on April 6, 2026, covering contract year 2027 policy across Medicare Advantage, Part D and the Medicare Cost Plan program. Insurers are already using 2026 to design the quality improvement programs and bid submissions that will govern 2027 coverage, which means the disparities mandate is gone for the plan year currently being built, not just for some distant future cycle.
Free retirement updates: The free Retirement Shield newsletter covers the benefits, deadlines, and money mistakes that cost retirees, a couple of times a week, in plain English. Subscribe free.
Utilization Management Committees Lose Their Health-Equity Requirements Too
The same rule strips a parallel set of requirements from MA Utilization Management Committees, the internal panels that review how plans decide on prior authorization requests. Plans will no longer have to seat a health-equity expert on that committee, conduct an annual analysis of how utilization management affects access to care across different enrollee groups, or post that analysis publicly. Those three requirements had existed to give outside observers a documented, plan-by-plan record of whether prior-authorization practices fell harder on some beneficiaries than others.
Removing the public-posting piece carries the most practical consequence for outside scrutiny. Those annual postings had been one of the few standardized windows into how an individual MA plan used prior authorization — a process federal watchdogs have repeatedly flagged for high denial rates that get reversed only after an appeal. Once the CY2027 quality improvement programs drop the posting requirement, that specific public record disappears with it, even though plans still operate utilization management committees under other, separate rules that remain in place.
CMS’s justification for both eliminations rests on the same “reducing regulatory burden and costs” framing tied to Executive Order 14192, the deregulation order the administration has applied across federal agencies since 2025. The fact sheet does not argue the health-equity analysis work was inaccurate or ineffective; it argues the requirement itself imposed cost and paperwork CMS wants removed from MA plan operations. That distinction matters for how the change should be read — it is a decision about who has to do the work, not a finding that the work failed.
The Star Ratings Money at Stake Behind the Rollback
Quality improvement programs are not a side exercise for MA insurers — they feed directly into the Star Ratings system CMS uses to calculate Quality Bonus Payments, the extra federal dollars a plan earns for scoring well. CMS’s own count puts MA plans that include drug coverage at up to 43 quality measures currently determining those scores. Those bonus dollars are what fund the lower premiums, reduced cost-sharing and extra benefits, such as dental or vision coverage, that MA plans advertise to pull beneficiaries away from traditional Medicare.
The fact sheet’s own language on the disparities changes addresses only removal — it does not describe a replacement measure, review, or reporting requirement that would preserve a disparities-focused check inside the Star Ratings system once the mandate is gone. That leaves a real question the rule itself does not answer: whether individual insurers keep funding health-equity-focused quality work now that it is optional, or whether it falls off each plan’s priority list once the requirement disappears.
The stakes are not confined to a narrow slice of the program. Medicare Advantage enrollment reached 55% of eligible Medicare beneficiaries in 2026, according to KFF’s enrollment tracking — about 35.2 million of the 64.2 million beneficiaries with both Medicare Part A and Part B. A change to what MA quality improvement programs must cover now applies, plan by plan, across the majority of Medicare’s population, not a narrow pilot group or a handful of insurers.
Nothing in the final rule requires CMS to report back on whether disparities-focused quality work continues without the mandate, and nothing in the fact sheet commits to tracking the outcome. The first real evidence will come from how MA plans actually build their 2027 quality improvement programs over the coming months — whether insurers keep the disparities work that used to be required, or let it lapse now that the federal government has stopped asking for it.
This article was produced with AI assistance and reviewed by The Money Overview editorial team.
More Financial Reading
